Chapter 7

Everolimus and sirolimus antagonize tacrolimus based calcineurin inhibition via competition for FK-binding protein 12

Huub H. van Rossum
Fred P.H.T.M. Romijn
Nico P.M. Smit
Johan W. de Fijter
Johannes van Pelt

Biochemical Pharmacology  2009, 77(7), 1206-1212
Chapter 7: Everolimus and sirolimus antagonize tacrolimus

Abstract

The calcineurin inhibitors cyclosporin A and tacrolimus and the inhibitors of the mTOR, sirolimus and everolimus bind immunophilins that are required for their immunosuppressive action. In contrast to cyclosporin A, tacrolimus and the mTOR inhibitors (MTIs) share common immunophilins, the FK506-binding proteins (FKBPs). We investigated the immunosuppressive interactions of MTIs on tacrolimus based immune suppression, since insights in immunological drug–drug interactions can be very relevant for optimization of immunosuppressive regimens in allograft transplantation medicine.

Isolated peripheral blood mononuclear cells from healthy volunteers were incubated with combinations of MTIs and calcineurin inhibitors and when monitored for calcineurin activity and IL-2 excretion after mitogen stimulation, tacrolimus IC\textsubscript{50} concentrations shifted to higher concentrations in the presence of MTIs. This antagonism was absent for cyclosporine A, reproducible for 10 healthy volunteers (p < 0.001) and stronger for sirolimus than for everolimus. When cell lysate was treated with and without MTI, tacrolimus and FKBP12, FKBP12 could increase calcineurin inhibition by tacrolimus and reverse the MTI antagonism for both MTIs.

These results demonstrate that FKBP12 can be rate limiting for calcineurin inhibition at high tacrolimus concentrations and that the antagonism of sirolimus and everolimus on tacrolimus based immune suppression is mediated via saturation of FKBP12.
Chapter 7: Everolimus and sirolums antagonize tacrolimus

Introduction

After organ transplantation, immune suppression to prevent allograft rejection is crucial for successful graft survival. Several immunosuppressive agents, such as the calcineurin (CN) inhibitors tacrolimus (TRL) or cyclosporin A (CsA) and the mammalian target of rapamycin (mTOR) inhibitors sirolimus (SRL) or its derivative everolimus (EVL), are used and combinational therapies are applied to achieve optimal immunosuppressive effect and reduce individual drug toxicity(1). CsA and TRL inhibit CN, a calcium/calmodulin dependent serine/threonine protein phosphatase that plays an important role in mediating T-cell receptor stimuli into cytokine (IL-2, IFNγ) transcription. SRL and EVL inhibit mTOR, a kinase with a key function in cell cycle progression(1,2). Both classes of drugs inhibit enzyme activity only after binding to specific intracellular binding proteins, so called immunophilins(3,4). CsA binds selectively to the cyclophilin class of immunophilins that are cytosolic peptidyl–prolyl isomerases, while TRL and the mTOR inhibitors (MTIs) bind to the FK506-binding proteins (FKBP) that also exert peptidyl–prolyl isomerase activity(3). SRL, EVL and TRL bind similar FKBP(5,6), while distinct and selective inhibition of respectively mTOR and CN is observed (7). Since similar FKBP are required for successful CN inhibition by TRL and mTOR inhibition by SRL or EVL, pharmacological drug–drug interactions have been investigated by several groups. Dumont et al. has shown that SRL and TRL are reciprocal antagonists(5,8), while others have demonstrated immunosuppressive synergism of these drugs(9,10).

In clinical practice, pharmacokinetic drug–drug interactions on metabolic and drug-transporter proteins are therapeutically avoided or adjusted for by therapeutic drug monitoring. When drug–drug interactions occur on the pharmacologic level and thus inhibit each others effectiveness, concentration measurement becomes less relevant since it is unable to detect this interaction(10). In addition, combinations of immunosuppressive drugs might be associated with immunosuppressive synergism(11). Pharmacodynamic monitoring strategies that can detect these interactions may prove to be useful to further optimize immunosuppressive regimen(12). In this respect we studied the interaction of EVL and SRL on TRL based immunosuppression in peripheral blood mononuclear cells (PBMCs) isolated from healthy individuals. Pharmacological interaction was investigated by measurement of CN enzyme activity. For immunological monitoring, the IL-2 downstream product of CN was used.
Chapter 7: Everolimus and sirolums antagonize tacrolimus

Materials and methods

Materials
The following materials and reagents were used: Buffy coat were purchased from Sanquin (Amsterdam, NL). RPMI 1640, heat inactivated fetal calf serum (iFCS), penicillin/streptomycin, phytohemagglutinin (PHA) and IL-2 EASIA kit from Invitrogen (Carlsbad, CA), NP-40, soybean trypsin inhibitor, cyclosporin A, tacrolimus, sirolimus (rapamycin), FKBP12 and phorbol-12-myristate-13-acetate (PMA) from Sigma–Aldrich (Steinheim, Germany). Phenylmethylsulfonyl fluoride from MERCK (Darmstadt, Germany), leupeptin from Roche (Basel, Switzerland), aprotinin from Bayer (Leverkusen, Germany), phosphate standard concentrate and everolimus from Fluka (Buchs, Switzerland) and the malachite green calcineurin activity assay kit from Biomol (Plymouth Meeting, PA). All other chemicals and reagents were of the highest available grade.

Immunosuppressants
The immunosuppressants CsA (MW 1203), TRL (MW 804), EVL (MW 958) and SRL (MW 914) were dissolved in ethanol and serial diluted in ethanol. These immunosuppressant stock solutions were diluted in the experiments resulting in final CsA, EVL and SRL concentrations of 0.025, 0.25, 2.5, 25, 250 and 2500 μg/L and final TRL concentrations of 0.00625, 0.0625, 0.625, 6.25, 62.5 and 625 μg/L. Final ethanol concentrations were 0.25% for single immunosuppressant experiments and 0.5% for the interaction experiments. For the CsA inhibition curve in Figure 7.2, CsA ranged from 0.1 to 3600 mg/L with final ethanol concentrations of 1%. The ethanol concentrations resulted in a 5% increase in CN activity when compared to an ethanol blank (n = 4, P = 0.04).

PBMC isolation and cell culture
Peripheral blood mononuclear cell (PBMC) fraction of healthy volunteer blood was isolated from buffy coats by ficoll density gradient centrifugation. Remaining of erythrocytes and thrombocytes were lysed and washed out by NH₄Cl lysis buffer (8.4 g/L NH₄Cl, 1.0 g/L KHCO₃, pH 7.3) and resuspended in phosphate buffered saline (PBS, 154 mmol/L NaCl, 1.4 mmol/L phosphate pH 7.5) for cell count on a Sysmex XE2100. Cells were centrifuged (10 min., 350g, 4 °C) and resuspended at a concentration of 2·10⁶ cells/mL in RPMI 1640 cell culture containing 10% iFCS, 100 U/mL penicillin and 100 μg/mL streptomycin.
For CN activity measurement, cells were incubated for 1 h at 37°C with immunosuppressant(s). After incubation, samples were centrifuged (10 min, 350g, 4°C) and cell pellets were washed once with 400 μL HEPES buffered saline (9.0 g/L NaCl, 10 mmol/L Hepes pH 7.5), resuspended in 400 μL lysis buffer (50 mmol/L Tris–HCl pH 7.7, 1.0 mmol/L dithiothreitol, 5.0 mmol/L ascorbic acid, 0.02% (v/v) NP-40, 50 mg/L soybean trypsin inhibitor, 50 mg/L phenylmethylsulphonyl fluoride, 5.0 mg/L leupeptin and 5.0 mg/L aprotinin) and lysed by 3 freeze thaw cycles (liquid N₂ /30°C). Cell debris was centrifuged (10 min, 10000g, 4°C) and supernatants were snap frozen in liquid N₂ before storage at -80°C till CN activity measurement(13).

For IL-2 excretion measurement, cells were stimulated by PHA/PMA 1 h after incubation with immunosuppressant(s), and incubated overnight at 37°C in a humidified environment (5%, CO2). PMA stock solution was 4000 times diluted in cell cultures resulting in a final PMA and DMSO concentration of respectively 5.3 nM and 0.025%, and PHA was 100 times diluted according to manufacturers’ protocol. The next day, cells were centrifuged (10 min, 350g, 4°C) and supernatant was stored at -20°C until IL-2 concentration measurement.

**Cell lysate experiments**

In order to investigate the role of FKBPs, we isolated PBMCs from buffy coats obtained from healthy volunteers. Untreated PBMCs were lysed as described before and aliquoted lysate was incubated in duplicate (1 h, 37°C) with and without TRL, MTI and FKBP12 resulting in final lysate concentrations of 25 μg/L TRL, 50 μg/L of SRL/EVL and 2000 μg/L and 10000 μg/L of extra FKBP12. At these concentrations the molar concentrations of the MTIs, TRL and FKBP12 were of the same order of magnitude. Directly after incubation CN activity was determined.

**Calcineurin assay**

Calcineurin phosphatase activity was measured as described before(13). In brief, CN phosphatase was quantified by measurement of the dephosphorylation of the phosphorylated RII substrate in the presence of okadaic acid. 15 μL of sample lysis was added to 40 μL of assay buffer (0.313 mmol/L calmodulin, 0.375 mmol/L RII phosphopeptide substrate, 75 mmol/L Tris pH 7.5, 150 mmol/L NaCl, 9 mmol/L MgCl₂, 0.75 mmol/L dithiothreitol, 0.0375% NP-40, 0.625 μmol/L okadaic acid, 0.75 mmol/L CaCl₂ and 5 mmol/L ascorbic acid) and substrate blanks were used to correct for background absorbance. The assay was run for 30 min. at 30 °C and stopped by addition of 100 μL of malachite green reagent. Colour was developed
the next 50 min. before absorbance measurement at 620 nm, and phosphate was quantified by means of a 0–5 nmol calibration curve.

**Cytokine concentration measurement**

IL-2 concentrations were determined with the EASIA kit (Invitrogen) and performed according to manufacturers’ protocol.

**Data analysis and statistics**

Values are presented as mean of duplicate and blank experiments were performed in quadruple. CN activity and IL-2 concentrations were expressed as % of blank measurement in order to remove inter-individual variation in absolute CN activity and IL-2 excretion. CN inhibition curves and IL-2 cytokine inhibition curves were fitted by sigmoidal dose–response curves using GraphPad software and IC$_{50}$ concentrations, Emax values and 95% confidence intervals (CI) were obtained from these regression analysis. Student t-tests were used to test significance and statistical significance was defined as P < 0.05.

**Results**

**IL-2 inhibition by TRL and CsA in the presence of EVL and SRL**

To gain insights whether and under which conditions the immunological interaction between the MTIs and TRL occurred, we first measured the effect of the MTIs on IL-2 inhibition by TRL. PBMCs isolated from healthy volunteers were stimulated using PHA/PMA and IL-2 excretion was measured in the presence of TRL or CsA and various concentrations of EVL or SRL. The results of these experiments are shown in figure 7.1 and the obtained IC$_{50}$ values of CsA and TRL in the presence of various concentrations of EVL and SRL are listed in table 7.1. The MTIs inhibited IL-2 excretion in the PHA/PMA stimulated PBMCs themselves at the concentration range used and this inhibition increased with increasing concentrations of MTI, though no clear sigmoidal concentration response relationship was visible as well as no inhibition of total IL-2 excretion. When high TRL concentrations were used in combination with EVL or SRL, low concentration of the MTIs did not significantly effect IL-2 inhibition by TRL.
Chapter 7: Everolimus and sirolums antagonize tacrolimus

Figure 7.1. IL-2 inhibition by TRL and CsA in the presence of MTIs. IL-2 inhibition by TRL was determined in the presence of various concentrations of SRL (A) and EVL (B). (C) and (D) show the CN inhibition by CsA in the presence of the same concentrations of SRL and EVL respectively. Data show the mean of duplicate measurement for one healthy individual.

<table>
<thead>
<tr>
<th>[mTOR inhibitor] in μg/L</th>
<th>Tacrolimus IC₅₀ in μg/L (95% CI)</th>
<th>Cyclosporin A IC₅₀ in μg/L (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sirolimus</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>0.20 (0.12 – 0.33)</td>
<td>8.5 (2.6 - 27)</td>
</tr>
<tr>
<td>0.25</td>
<td>0.14 (0.09 – 0.23)</td>
<td>2.7 (1.1 - 6.7)</td>
</tr>
<tr>
<td>2.5</td>
<td>0.22 (0.11 – 0.44)</td>
<td>2.1 (1.1 - 4.1)</td>
</tr>
<tr>
<td>25</td>
<td>1.6 (0.57 - 4.6)</td>
<td>4.7 (2.4 - 9.2)</td>
</tr>
<tr>
<td>250</td>
<td>11 (4.8 - 26)</td>
<td>1.2 (0.35 - 4.1)</td>
</tr>
<tr>
<td>2500</td>
<td>114 (56 – 234)</td>
<td>0.59 (0.05 - 6.8)</td>
</tr>
<tr>
<td>Everolimus</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>0.15 (0.06 – 0.36)</td>
<td>9.5 (4.7 - 19)</td>
</tr>
<tr>
<td>0.25</td>
<td>0.13 (0.05 – 0.31)</td>
<td>3.6 (2.1 - 6.3)</td>
</tr>
<tr>
<td>2.5</td>
<td>0.13 (0.05 – 0.38)</td>
<td>4.7 (2.9 - 7.5)</td>
</tr>
<tr>
<td>25</td>
<td>0.28 (0.14 – 0.55)</td>
<td>2.1 (0.84 - 5.0)</td>
</tr>
<tr>
<td>250</td>
<td>2.6 (1.4 - 4.6)</td>
<td>5.6 (3.1 - 10)</td>
</tr>
<tr>
<td>2500</td>
<td>19 (11 - 32)</td>
<td>2.0 (0.84 - 4.9)</td>
</tr>
</tbody>
</table>

Table 7.1. IL-2 IC₅₀ values of TRL and CsA in the presence of various concentrations of SRL and EVL. IC₅₀ values and 95% confidence intervals (CI) were obtained from the sigmoidal concentration–response regressions when the data in Figure 7.1 are presented with the CNI inhibitor on the x-axis and the individual curves are variations in EVL or SRL concentrations.

However at higher concentrations (250 μg/L), significant shifts in IL-2 IC₅₀ values were observed. MTI concentrations of 25 μg/L and higher reversed IL-2 inhibition by TRL though the occurrence and magnitude of this effect is also dependent on
the TRL concentration and seems to be less for EVL when compared to SRL (figure 7.1A and B). No increasing IC\textsubscript{50} values and significant differences in IC\textsubscript{50} values were observed when CsA was used in combination with SRL and EVL (figure 7.1C and D).

**CN inhibition by CNIs, MTIs and combinations thereof**

To further investigate the origin of the observed IL-2 antagonism, we measured calcineurin activity that is the pharmacological target enzyme of TRL. First, the individual effect of the immunosuppressants on CN activity was investigated and therefore CN inhibition curves were determined for CsA, TRL, EVL and SRL. The data in Figure 7.2 show that SRL and EVL do not inhibit CN activity, while for TRL and CsA a clear dose–response curve was found with an IC\textsubscript{50} value of 1.0 µg/L (0.51–2.1 µg/L, 95% CI) and an E\textsubscript{max} of 53% (48–58%, 95% CI) for TRL and an IC\textsubscript{50} value of 14 µg/L (9.6–21 µg/L, 95% CI) and an E\textsubscript{max} of 31% (26–36%, 95% CI) for CsA.

![Figure 7.2. CN inhibition by CsA, TRL, SRL and EVL.](image)

Data are normalized and expressed as % by dividing through CNI blank measurement (performed in quadruple) and maximum effect was fixed at 100% for the sigmoidal dose–response analysis in GraphPad. Data are presented as mean of duplicate measurement.

Next, we incubated five concentrations of TRL (0.0625–625 µg/L) and a TRL blank, each in combination with five concentrations (0.25–2500 µg/L) and a blank of either EVL or SRL. As control experiment TRL was replaced by CsA (0.25–2500 µg/L). The obtained CN inhibition curves are shown in figure 7.3 and the calculated IC\textsubscript{50} concentrations for TRL and CsA in the presence of various concentrations of EVL and SRL are listed in table 7.2.
Chapter 7: Everolimus and sirolums antagonize tacrolimus

Figure 7.3. CN inhibition by CsA and TRL in the presence of MTIs. CN inhibition by TRL was determined in the presence of SRL (A) and EVL (B). (C) and (D) show the CN inhibition by CsA in the presence of the same concentrations of SRL and EVL respectively. Data show the mean of duplicate of one healthy individual and the lines are the CN inhibition curves of TRL and CsA in the presence of various concentrations of EVL and SRL fitted for sigmodial dose–response curves by GraphPad software. The IC₅₀ values for CsA and TRL obtained from these curves are listed in table 7.2. Data were normalized by dividing through blank measurement in the absence of CNI and MTI. CNI 0 values were set at 10⁻⁴ μg/L for the regression analysis.

<table>
<thead>
<tr>
<th>[mTOR inhibitor]</th>
<th>Tacrolimus in μg/L (95% CI)</th>
<th>Cyclosporin A IC₅₀ in μg/L (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>[μg/L]</td>
<td>IC₅₀ in μg/L</td>
</tr>
<tr>
<td>Sirolimus</td>
<td></td>
<td>IC₅₀ in μg/L (95% CI)</td>
</tr>
<tr>
<td></td>
<td>0</td>
<td>1.0 (0.32 - 3.4)</td>
</tr>
<tr>
<td></td>
<td>0.25</td>
<td>1.5 (0.69 - 3.4)</td>
</tr>
<tr>
<td></td>
<td>2.5</td>
<td>3.8 (1.6 - 8.8)</td>
</tr>
<tr>
<td></td>
<td>25</td>
<td>11 (6.7 - 18)</td>
</tr>
<tr>
<td></td>
<td>250</td>
<td>125 (25 – 620)</td>
</tr>
<tr>
<td></td>
<td>2500</td>
<td>290 (0.08 - 1.1·10⁶)</td>
</tr>
<tr>
<td>Everolimus</td>
<td></td>
<td>IC₅₀ in μg/L (95% CI)</td>
</tr>
<tr>
<td></td>
<td>0</td>
<td>0.54 (0.15 – 1.9)</td>
</tr>
<tr>
<td></td>
<td>0.25</td>
<td>0.70 (0.34 – 1.4)</td>
</tr>
<tr>
<td></td>
<td>2.5</td>
<td>1.2 (0.39 - 3.9)</td>
</tr>
<tr>
<td></td>
<td>25</td>
<td>4.6 (0.91 – 23)</td>
</tr>
<tr>
<td></td>
<td>250</td>
<td>20 (3.7 - 104)</td>
</tr>
<tr>
<td></td>
<td>2500</td>
<td>320 (0.21 - 5.0·10⁵)</td>
</tr>
</tbody>
</table>

Table 7.2. CN IC₅₀ values of TRL and CsA in the presence of various concentrations of SRL and EVL. IC₅₀ values and 95% confidence intervals (CI) were obtained from the sigmoidal concentration–response regressions presented in figure 7.3 by GraphPad software.
Chapter 7: Everolimus and sirolimus antagonize tacrolimus

A concentration dependent effect of EVL and SRL on CN inhibition by TRL was observed and significant higher TRL IC₅₀ values were found when 25 μg/L SRL and 250 mg/L EVL or higher, were present in culture medium (figure 7.3A and B). This pattern was not detected for the CsA CN inhibition curves; here no differences in IC₅₀ values were observed by increasing concentration of MTIs (figure 7.3C and D).

Antagonism of MTIs on TRL based immune suppression in 10 healthy volunteers

To determine whether the TRL/MTI interactions are reproducible for other individuals we investigated the interaction on PBMCs isolated from 10 healthy volunteers. For reproduction of the immunological antagonism we reproduced the experiment for 10 healthy volunteers and treated the PBMCs with 0.625 μg/L TRL and 25 μg/L EVL or SRL, concentrations that previously (figure 7.1) showed to be characteristic for the interaction. The results are shown in figure 7.4.

![Figure 7.4. MTI antagonism in 10 healthy volunteers.](image)

- All three drugs inhibited IL-2 excretion in our cell culture system, though TRL caused a larger inhibition than SRL (P = 0.001) and EVL (P = 0.002) that partially inhibited the IL-2 excretion in these concentrations. When combinations of TRL and MTIs were tested, SRL significantly reversed IL-2 excretion inhibition by TRL (P = 0.004), while for EVL no difference in IL-2 levels was found (P = 0.53). The IL-2
Chapter 7: Everolimus and sirolums antagonize tacrolimus

concentrations observed for the EVL/TRL combination was also significant lower when compared to the combination of SRL/TRL ($P = 0.01$).

Next, we determined CN activity in the presence/absence of TRL (6.25 µg/L) and/or EVL/SRL (25 µg/L), concentrations that were previously illustrative for the interaction (figure 7.3).

Here no CN inhibition was found for SRL and EVL. TRL caused a mean CN inhibition of $44 \pm 11\%$ (SD) in the PBMC fractions isolated from these individuals. When MTIs were co-incubated with TRL in the culture medium, CN inhibition by TRL was partially lost and final mean inhibition in the presence of SRL and EVL was $18 \pm 14\%$ and $26 \pm 10\%$, respectively. Both were significant lower ($P < 0.001$) when compared to TRL alone. Antagonism of SRL on TRL mediated CN inhibition was significantly larger than that of EVL for these concentrations ($P = 0.01$).

Role of FKBP12s

To investigate whether the mechanism of antagonism between both mTOR inhibitors and TRL was mediated via competition for saturated FKBP binding sites, we prepared PBMC lysate from untreated cells of 4 healthy volunteers in duplicate and incubated (1 h, 37 °C) these with and without mTOR inhibitor, TRL and FKBP12. CN activity was determined directly after incubation. The results of these experiments are shown in figure 7.5.

Figure 7.5. CN activity after FKBP12, TRL and MTI addition to cell lysate. CN activity was determined in PBMC lysate in the presence/absence of TRL, FKBP12 and either SRL or EVL and expressed as % of blank measurement. Final concentrations were 25 µg/L TRL, 50 µg/L of SRL/EVL and 0, 2000 and 10000 µg/L of FKBP12 was added to cell lysate. Results were obtained from duplicate measurement of 4 healthy volunteers and presented as mean W SEM. Statistical analysis were performed between TRL and TRL + SRL or EVL conditions, except when lines indicate otherwise and presented as (***$)$ for $P < 0.001$ and NS for not significant.
Chapter 7: Everolimus and sirolums antagonize tacrolimus

In this test system no inhibition of CN was found by the MTIs, FKBP12 and combinations thereof (data not shown). Inhibition by TRL in cell lysate was observed though it was much smaller (±10%) compared to the cell systems. Since the addition of 2000 µg/L FKBP12 increased TRL inhibition (±35%, P < 0.001) it seemed that the FKBP12 pool from the intracellular compartment was diluted in the cell lysate, limiting CN inhibition by TRL. Addition of SRL to TRL reduced TRL inhibition of CN (P = 0.005), while for EVL antagonism under these conditions could not be detected (P = 0.7). In the presence of 2000 µg/L FKBP12 antagonism for both SRL and EVL was found (for both P < 0.001) and when 10000 µg/L FKBP12 was used, antagonism of both MTIs was no longer observed.

Discussion

In transplant recipients, multiple immunosuppressive agents are normally used in order to optimally prevent acute rejection episodes and to reduce the side effects of the individual drugs(1). The CNI and MTI class of drugs require intracellular binding proteins (immunophilins) to exert their immunosuppressive action. TRL binds to its intracellular binding proteins (FKBPs) and especially the 12 kDa protein FKBP12 is considered critical for the immunosuppressive action of TRL(14). The MTIs SRL and its analog EVL require binding to the same protein though another immunosuppressive mechanism is observed for these drugs(6,15). Where TRL inhibits CN and block T-cell receptor induced activation/proliferation of T-cells, the mTOR inhibitors inhibit IL-2 induced T-cell proliferation(7,15). In this study, using a CN assay, we confirmed that CN enzyme activity is not inhibited by EVL and SRL but selectively by TRL and CsA (figure 7.2), which is in agreement with previous observations.

In studies by Dumont et al., reciprocal antagonism was observed for SRL and TRL which was explained by the use of similar intracellular binding sites of the drugs(5,8). Here we show that both SRL and EVL antagonize TRL mediated CN inhibition and TRL inhibition of IL-2 excretion in PHA/PMA stimulated PBMCs, an effect which is not observed for the CNI CsA. In addition, we show that the antagonism between MTIs and TRL in cell lysate is reversed by the addition of excess of FKBP12 (10000 µg/L), indicating that the antagonism is mediated via this protein. The in vitro antagonism observed in our cellular system is significant starting at SRL concentrations of 25 µg/L for CN activity and 250 µg/L for IL-2 excretion and at EVL concentrations of 250 µg/L for both CN inhibition and IL-2
Chapter 7: Everolimus and sirolimus antagonize tacrolimus

excretion inhibition by TRL. These relative high concentrations of MTIs in combination with TRL seem to saturate FKBP binding sites that are required for CN inhibition by TRL. Competition between the MTIs and TRL for these binding sites is clearly illustrated by the IL-2 interaction experiments in figure 7.1. Here it is shown that 0.625 µg/L TRL itself inhibits IL-2 excretion, but when increasing concentrations of SRL are introduced, above a certain threshold (25 µg/L SRL), IL-2 inhibition by TRL is lost and the IL-2 response is more comparable to the 25 µg/L SRL response itself.

The MTIs themselves reduce IL-2 excretion in our cell culture system, without showing a clear sigmoidal concentration– response relationship. This effect is probably best explained to be indirect and mediated through inhibition of proliferation/activation of IL-2 producing cells. In our system the lowest MTIs concentrations used already significantly decreased IL-2 excretion. Under these conditions of low MTI concentration, immunosuppressive additivity or even synergism could be very well achieved in patients in combination protocols with CsA, but also TRL; although MTIs are mechanistically antagonists of TRL, antagonism only occurs at saturating conditions for FKBP. Immunosuppressive synergy has been demonstrated for SRL/TRL and SRL/CsA combinations on lymphocyte proliferation and lymphocyte activation markers(10).

25 µg/L of both EVL and SRL partially reversed CN inhibition by 6.25 µg/L TRL though the interference by SRL was significant larger when compared to EVL in 10 healthy volunteers. In addition, only SRL could significantly reverse IL-2 inhibition by 0.625 µg/L TRL. These results indicate relevant differences between both MTIs that could be explained by the weaker binding of EVL to FKBP12(6).

Kung and Halloran showed that at high concentrations of CNIs, immunophilins limit CN inhibition for both CsA and TRL(16). It is however not known whether this is relevant for CNI treated patients. When using combination immunosuppressant therapy of both MTI and TRL, saturation of FKBPs and thus pharmacological drug–drug interaction is even more likely and this interaction could therefore be clinically relevant. The MTI concentrations for which TRL antagonism was observed (25 µg/L) are of the same magnitude of MTI blood concentrations in allograft recipients treated with these drugs(17). In addition, also the TRL concentrations at which the interference was observed are found in allograft recipients treated with this drug(17). The drug concentrations that are used in our in vitro model can however not directly be translated to full blood drug concentrations, since drug concentrations from cell culture experiments do not necessarily show similar cellular responses compared to drug concentrations in blood due to the presence
Chapter 7: Everolimus and sirolumns antagonize tacrolimus

of irrelevant binding sites as has been demonstrated for CsA(18). The true clinical relevance remains therefore unclear.

If CN inhibition is limited by the immunophilin content in patients receiving CNI, this could be of great importance; higher CNI concentrations are ineffective. Especially early after graft implantation, when the blood concentrations are highest, this might become relevant. Consequently, under condition of immunophilin saturation, inter-individual variation in the content of immunophilins could be of great importance for allowing different maximal CN inhibitions.

Finally, blood drug concentrations and also intracellular drug concentrations are not able to detect the limitation of CN inhibition by immunophilins. Only pharmacodynamic strategies are theoretically capable of detecting these. This also holds for detecting the interaction between the MTI and TRL in individuals receiving both drugs.

In conclusion, it is shown that mTOR inhibitors can antagonize TRL and not CsA mediated immunosuppression. FKBP12 that is bound by EVL and SRL, and required for TRL based CN inhibition is a key mediator; saturation of this protein by high concentrations of MTIs and TRL results in competition for FKBP12.

References

Chapter 7: Everolimus and sirolums antagonize tacrolimus


